迪哲医药 (Dizal Pharma)
3 known investors
Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
Investors · 3
Competitors · 3
by search overlapBioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Zentalis6 shared keywordsZentalis is a clinical-stage pharmaceutical company developing azenosertib, an investigational oral therapy that inhibits WEE1 kinase to disrupt the cell-cycle safeguards cancer cells use to survive. It focuses on providing physicians and patients with a targeted, non-chemotherapy oral treatment option in oncology.
Dialectic Therapeutics5 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies competing with 迪哲医药 (Dizal Pharma) for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does 迪哲医药 (Dizal Pharma) do?
- Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
- Who are 迪哲医药 (Dizal Pharma)'s investors?
- 迪哲医药 (Dizal Pharma)'s investors include HongShan Capital Group, LAV, Lilly Asia Ventures.